Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.10% | -5.57% | -22.94% | -31.51% | -82.15% |
| Total Depreciation and Amortization | -2.59% | -1.27% | 2.26% | 8.15% | 7.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.94% | 13.40% | 17.82% | 54.85% | 28.83% |
| Change in Net Operating Assets | -950.85% | -27.74% | 263.14% | 3,750.57% | 110.29% |
| Cash from Operations | 9.72% | -12.24% | -8.03% | 45.99% | -39.47% |
| Capital Expenditure | 31.94% | 7.07% | 88.68% | -195.77% | 85.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.21% | -390.14% | -667.29% | -48.93% | 198.64% |
| Cash from Investing | -66.60% | -393.82% | -675.19% | -49.23% | 283.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.14% | -53.43% | -41.98% | 34.63% | -8.52% |
| Issuance of Common Stock | -93.96% | 3,487.66% | 2,310.92% | -84.13% | 13,851.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -82.98% | -- | -- |
| Cash from Financing | -94.13% | 7,174.81% | 25,405.21% | -84.25% | 17,302.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.97% | -603.21% | 2,456.02% | -617.79% | 1,049.94% |